Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2018 - 2019)

Zevra Therapeutics' Long-Term Deferred Tax history spans 4 years, with the latest figure at $67.7 million for Q4 2019.

  • For Q4 2019, Long-Term Deferred Tax rose 12.2% year-over-year to $67.7 million; the TTM value through Dec 2019 reached $67.7 million, up 12.2%, while the annual FY2019 figure was $67.7 million, 12.2% up from the prior year.
  • Long-Term Deferred Tax reached $67.7 million in Q4 2019 per ZVRA's latest filing, up from $60.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $67.7 million in Q4 2019 to a low of $29.1 million in Q4 2015.
  • Average Long-Term Deferred Tax over 3 years is $52.4 million, with a median of $60.4 million recorded in 2018.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 59.33% in 2015, then increased 12.2% in 2019.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $29.1 million in 2015, then soared by 107.41% to $60.4 million in 2018, then rose by 12.2% to $67.7 million in 2019.
  • Per Business Quant, the three most recent readings for ZVRA's Long-Term Deferred Tax are $67.7 million (Q4 2019), $60.4 million (Q4 2018), and $29.1 million (Q4 2015).